CURRICULUM VITAE

Mark F. Lew, M.D.
Professor of Neurology

A. PERSONAL INFORMATION

Business Address:	Department of Neurology USC/Keck School of Medicine Healthcare Consultation Center II 1520 San Pablo Street, Suite 3000 Los Angeles, California 90033
Business Telephone:	(323) 442-5728
Business Fax:	(323) 442-5794
Email:	mlew@surgery.usc.edu

B. EDUCATION

High School:	Polytechnic Preparatory Country Day School Brooklyn, New York Grades 5-12
University:	Johns Hopkins University Baltimore, Maryland B.A. with Honors in Psychology, 1981
Medical School:	George Washington University Medical Center Washington, D.C. M.D. Degree, 1987
Internship:	Internship in Internal Medicine George Washington University Hospital Washington, D.C. 1987-1988
Residency:	Residency in Neurology LAC+USC Department of Neurology Los Angeles, California 1988-1991
Fellowship:	Fellowship in Movement Disorders University of Southern California Department of Neurology Division of Movement Disorders Los Angeles, California 1991-1992
Licensure:	FLEX 1987 California State License, AO 45068 1988 DEA Registration 1988

Board Certification:	American Board of Psychiatry and Neurology, 1993

C. PROFESSIONAL BACKGROUND

Academic Appointment:

Professor of Neurology, Division of Movement Disorders
Keck School of Medicine, University of Southern California
2003-

Associate Professor of Neurology, Division of Movement Disorders
Keck School of Medicine, University of Southern California
1998- 2003

Assistant Professor of Neurology, Division of Movement Disorders
Keck School of Medicine, University of Southern California
1992-1998

Clinical Instructor of Neurology, Department of Neurology
Keck School of Medicine, University of Southern California
1991-1992

Specific Teaching Responsibilities:

Department of Neurology

General Neurology. Ward and Consult Attending
LAC+USC Medical Center with fellows, residents, and medical students two to three months per year. 1991-

LAC+USC Movement Disorders Clinic Attending
One- half day per month directly supervising residents, fellows and medical students
1991-

LAC+USC General Neurology Clinic Outpatient Attending
One-half day per month supervising residents, students 1992-

USC Movement Disorders Clinic Attending
2-3 full days per week of outpatient care and supervising residents, fellows and students
1992-

USC University Hospital Consult Attending 1- 2 months per year supervising residents
1992-

Specific Administrative Responsibilities:

Director, Movement Disorders Clinic
Department of Neurology
LAC+USC Medical Center, 1991-

Associate Director, Division of Movement Disorders,
Department of Neurology, 1992-1998

Director, Division of Movement Disorders
Department of Neurology, 1998-

University Service

Department of Neurology

Residency Selection and Review Committee 1993-

Faculty Practice Business Committee 1993-

Director, Neurology Clerkship, Medical Student Curriculum 1996- 1999

Co-Director, Neurobehavior Science Course, Year II 1996- 1999

Director Neurology Residency Program 2000- 2004

Faculty Practice Executive Committee 2001-

Chair, Faculty Practice Executive Committee 2002-

Chief Medical Officer USCNI 2004-

Vice Chairman Department of Neurology 2004-

School of Medicine

Interviewer, Medical School Admissions 1995-

Year III Curriculum Committee 1996- 2000

Clinical Science Student Performance Committee 1997- 2000

Educational Policy Committee 1997- 2000

Member, Institutional Review Board Committee, 1999-2004

Local Advisory Committee for the GCRC, 2001- 2004

Graduate Medical Education Committee, 2001- 2004

Central Advisory Committee for the GCRC Program, 2004-

Health Research Association (HRA) Board of Directors 2008-

Health Research Association Board of Directors Executive Committee 2009-

Health Research Association Operations committee 2009-

Co-Chair Training and Career Development Committee, Clinical Research Retreat, KSOM 3/14/09

Professional Service

Medical Director, Movement Disorders Program
San Diego Rehabilitation Institute
San Diego, California 1996- 2003

Ad Hoc Journal Reviewer—Neurology 1997-

Ad Hoc Journal Reviewer—Movement Disorders 2000-

Ad Hoc Journal Reviewer--- JNNP 2004-

Ad Hoc Reviewer for AJM, 2005

Ad Hoc Journal Reviewer- Clinical Neuropharmacology 2006-

Ad Hoc Reviewer- Drugs 2006-

Ad Hoc Reviewer – Drugs and Aging 2007-

Ad Hoc Reviewer- Neuropsychiatric Review and Treatment 2007-

Ad Hoc Reviewer- Expert Review of Opthalmology 2007-

Ad Hoc Reviewer- Journal of Neural Transmission 2008-

Ad Hoc Reviewer- Neurosurgery 2008-

Ad Hoc Reviewer- International Journal of Neuroscience-2010

Ad Hoc reviewer World Neurosurgery- 2010

Advisory Board member American Pharmacists Association (APhA) New Product Bulletin on Azilect

Participating Scientist. Parkinson Study Group (PSG)
(Consortium of academic Movement Disorders specialists, by invitation, recognized for their work in Parkinson's disease), headed by Ira Shoulson, M.D., University of Rochester 1994-

Participating Scientist. Dystonia Study Group (DSG)
(Consortium of academic neurologists studying the etiologies, mechanism and treatment of Dystonia) 1996-

Dystonia Medical Research Foundation
Therapeutics Trials Subcommittee, 1998- 2004

Executive Committee, Dystonia Study Group, 1999-2006

Advisory Panel Movement Disorders Society Dystonia/Spasticity Workshops, 2003-

Medical Advisory Committee of the Musicians with Dystonia Program, 2004-

ACP Medicine Peer Review Board, 2004-

WE Move Education Committee, 2005-

Editorial Board Simpson Healthcare Monographs in PD 2006-

Dystonia/ Spasticity Advisory Board, AAN 2007-

Dystonia Workshop Advisory Panel –AAN 2009 -

Other Significant Employment or Activities:

Testimony before the California State Senate Budget and fiscal Review Committee, Subcommittee #3 on Health, Human Services and Veterans Affairs regarding establishing a satellite Parkinson's outreach and treatment program at USC. April 21, 1999

Testified before the State of California Assembly Subcommittee #1 on Health and Human Services regarding establishing a satellite Parkinson's outreach and treatment program at USC. May 10, 1999

Courses Taught:

Movement Disorders Review Internal Medicine Board Review, Pasadena, California, August 1992

Allergan Pharmaceuticals Training Seminar—Clinical Uses of Botulinum Toxin, Newport Beach, California, December 1992

Use of Botulinum Toxin for the Treatment of Focal Dystonias: A Workshop, Workshop Director. USC/University Hospital, Los Angeles, California, June 1993

Clinical Workshop in the Use of Botulinum Toxin, Course Director, Madigan Medical Center, Fort Lewis, Washington, September 1993

American Academy of Neurology, Treatment of Dystonia: Workshop Demonstrating the use of Botulinum Toxin, San Diego, California, November 1993

Current Treatment of Parkinson's disease, American College of General Practice in Osteopathic Medicine and Surgery of California, Irvine, California, November 1993

New Approaches to Treating the Dystonic Patient, Allied Neuroscience Symposia: Part V, Movement Disorders, USC Departments of Neurology and Neurological Surgery and USC University Hospital, Los Angeles, California, June 1994

Movement Disorders, Course Director, Madigan Medical Center, Fort Lewis Washington, December 1994

The Treatment of Dystonia with Botulinum Toxin International Conference on Movement Disorders Seville, Spain, May 1995

New Advances in the Treatment of Parkinson's Disease International Conference on Movement Disorders, Seville, Spain, May 1995

Movement Disorders, USC Family Practice Intensive Refresher Course, Glendale, California June 23, 1995

Clinical Usefulness of Botulinum Toxin for the Treatment of Dystonia and Other Muscle Spasms, Faculty, American Academy of Neurology 48th Annual Meeting, March 29, 1996

New Uses for Botulinum Toxin, Madigan Medical Center, Tacoma, Washington, December 13, 1996

Botulinum Toxin Injections for Abnormal Facial Movements, American Academy of Facial Plastic and Reconstructive Surgery, Reconstructive and Plastic Surgery of the Head and Neck, Pasadena, California, February 20-23, 1997

Neurological Disorders Affecting Gait, Doctorate of Physical Therapy Course: Differential Diagnosis, Los Angeles, California, April 1997

Botulinum Toxin: Treatment of Dystonia, Hemifacial Spasm and Other Disorders, Mayo Clinic, Scottsdale, Arizona, November 1997

Treatment of Dystonia and Spasticity, AAN Workshop, San Francisco, California, October 1999

Treatment of Dystonia: Demonstrating the use of Botulinum toxin, Course Director, AAN Workshop, Los Angeles, California, December 2002

Treatment of Dystonia and Spasticity with Botulinum Toxin, AAN/MDS workshops, Denver Colorado 2003

Treatment of Dystonia and Spasticity with Botulinum Toxin, AAN/MDS workshops, Dallas, Texas 2004

Practical management of motor complications in Parkinson' disease. Course Director, October 2004, AAN Workshop

Treatment of Dystonia and other Disorders with botulinum toxins. Course/ Workshop Director, June, 2006, Los Angeles, Ca

Treatment of Dystonia and other Disorders with botulinum toxins. Course/ Workshop Director, September, 2006, Los Angeles, Ca

The Many Faces of Dystonia: A Poorly Diagnosed and Recognized Disorder. An Interactive Video Workshop. Movement Disorders Society November 2006, Chicago, Illinois

Treatment of Dystonia and other Disorders with botulinum toxins. Course/ Workshop Director, December, 2006, Los Angeles, Ca

The Many Faces of Dystonia: A Poorly Diagnosed and Recognized Disorder. An Interactive Video Workshop. December 2006, Chicago, Los Angeles, Ca Movement Disorders Society Course Director

The Uses of Botulinum Toxin for the treatment of Dystonia and Spasticity Workshop October 2007 San Diego Course Instructor

The Many Faces of Dystonia : A Frequently Misdiagnosed Disorder: An Interactive Workshop Sponsored by the Movement Disorders Society Course Instructor March 2008 Boston, Mass

36th Annual Diagnostic and Therapeutic Skills in Internal Medicine Department of Internal Medicine, USC School of Medicine Course. Faculty Kona , Hawaii March 2008 Neurology Lectures

Neurotoxin Institute Workshop on Cervical Dystonia and Sialorrhea. Faculty Los Angeles, Ca, April 2008

37th Annual Diagnostic and Therapeutic Skills in Internal Medicine Department of Internal Medicine, USC School of Medicine Course. Faculty Maui , Hawaii August 2008 Neurology Lectures

The Many Faces of Dystonia : A Frequently Misdiagnosed Disorder: An Interactive Workshop Sponsored by the Movement Disorders Society Course Instructor November 2008 Dallas, Texas

The AAN Uses of Botulinum Toxin for the treatment of Dystonia and Spasticity Workshop November 2009 Course Instructor, Las Vegas, Nevada

39th Annual Diagnostic and Therapeutic Skills in Internal Medicine Department of Internal Medicine, USC School of Medicine Course. Faculty Kona , Hawaii March 2010 Neurology Lectures

USC/Keck School of Medicine First Annual PD Summit Course Director. Los Angeles Ca December 2010

Additional Community Service

Invited Grand Rounds

Update in the management of Parkinson's disease, Valley Hospital, Las Vegas, Nevada, August 1991

New advances in the treatment of Parkinson's disease, Desert Springs Hospital, Las Vegas,

Advances in Parkinson's disease, Redding Medical Center, Redding, California, February 1992

Parkinson's disease update, Overlake Hospital, Bellevue, Washington, March 1992

Advances in Parkinson's disease, Kern Medical Center, Bakersfield, California, May 1992

Update in the management of Parkinson's disease, Allenmore Hospital, Tacoma, Washington, September 1992

Treatment of spasmodic dysphonia, The treatment of dystonia—an update, California Parkinson Foundation, San Jose, California October 1992

Advances in Parkinson's disease, Consultants in Medicine, Bellingham, Washington, March 1993

Treatment of hypertonicity and dystonia, Alvarado Hospital Medical Center and San Diego Rehabilitation Institute, San Diego, California, June 1993

Advances in Parkinson's disease, Stevens Memorial Hospital, Edmonds, Washington California, September 1993

New developments in the treatment of Parkinson's disease, Merle West Medical Center, Klamath Falls, Oregon, January 1994

Therapeutic approaches to Parkinson's disease, VA Medical Center, Fresno, California, February 1994

Therapeutic approaches to Parkinson's disease, Valley Medical Center, Fresno, California, February 1994

New developments in the treatment of Parkinson's disease, Pacific Alliance Medical Center, Los Angeles, California June 1994

Clinical uses of botulinum toxin, Alvarado Hospital San Diego, March 1997

An update on new treatments for movement disorders, San Diego Rehab Institute, San Diego, December 1997

Parkinson's disease, Monterey Park Hospital, Monterey Park, California, April 1999

Treatment of Parkinson's disease, Santa Barbara Cottage Hospital April 1999
Movement disorders above the clavicles, Department of Otolaryngology/Head and Neck Surgery, University of Southern California School of Medicine, May 1999

Treatment options for dystonia. Tulane Medical School/Louisiana State University. September 1999

Parkinson's disease: An Overview, UNLV School of Medicine Department of Medicine, March, 2005

New therapies for Parkinson's disease. UCLA School of Medicine, Department of Neurology, October 2005

New treatments for PD 2006. Kaiser Permanente Yearly Neurology Symposium, Anaheim California. March 2006

New therapies for PD in 2006. Grand Rounds West LA, Sepulveda VA. May 2006

New Treatments for PD. Grand Rounds Harbor UCLA July 2006

New Treatments for PD. Grand Rounds Kaiser Panorama City December 2006

Current Treatment of Restless Legs Syndrome.Grand Rounds Harbor UCLA Medical Center March 2007

New Therapies and Neuroprotection in PD. Grand Rounds Kansas University Medical Center (KUMC) May 2007

Neuroprotection in PD. Orange County Neurologic Society September 2007

New Therapies in Restless Legs Syndrome UCSD Grand Rounds September 2007

Rasagiline for the Treatment of Parkinson's Disease VI Latin American Congress on Movement Disorders, Maracaibo, Venezuela November 2007

Neurology Grand Rounds Kaiser Sunset, Los Angeles, Ca January 2010 Treatment of Early PD

Review of Movement Disorders: A Video Extravaganza. Grand rounds UNLV School of Medicine 12/2010

Review of Movement Disorders. Grand Rounds Harbor UCLA 1/2011

Other Invited Lectures

Current therapy in Parkinson's disease, Panorama Community Hospital, Panorama City, California May 1991

Advances in Parkinson's disease, Alhambra Community Hospital, Alhambra, California May 1991

Parkinson's disease update, Fontana Medical Group, Fontana, California, July 1991

New advances in the treatment of Parkinson's disease, Verdugo Hills Hospital, Glendale, California, September 1991

Parkinson's disease update, Santa Marta Hospital, Los Angeles, California, October 1991

Advances in Parkinson's disease, Riverside Medical Groups, Riverside, California. October 1991

Update in the management of Parkinson's disease, Granada Hills Community Hospital Granada Hills, California, February 1992

New advances in the Treatment of Parkinson's disease, Monterey Park Community Hospital, Monterey Park, California, March 1992

Update in the management of Parkinson's disease, Charter Suburban Community Hospital, Paramount, California, March 1992

Tourette's syndrome, Torrance Memorial Hospital, Torrance, California, July 1992

Controversies in Neurology: Surgical vs. medical treatment of hemifacial spasm, L.A. Society of Neurological Sciences, Los Angeles, California, September 1992

Treatment of spasmodic dysphonia, The treatment of dystonia—an update, University of Southern California, Los Angeles, California, October 1992

Parkinson's disease update, Humana Hospital, Anaheim, California, December 1992

Clinical use of botulinum toxin, Cedars Sinai Hospital, Los Angeles, California, February 1993

Clinical use of botulinum toxin, St. Joseph's Hospital, Burbank, California, March 1993

Clinical use of botulinum toxin, Arcadia Methodist Hospital, Arcadia, California, April 1993

Parkinson's disease update, LAC+USC Medical Center, Los Angeles, California, July 1993

Advances in Parkinson's disease, Santa Marta Hospital, Los Angeles, California, July 1993

Clinical use of botulinum toxin, Verdugo Hills Hospital, La Canada, California, July 1993

Clinical use of botulinum toxin, Monterey Park Hospital, Monterey Park, California, August 1993

Uses of botulinum toxin in clinical medicine, Department of Internal Medicine, LAC+USC Medical Center, Los Angeles, California September 1993

Uses of botulinum toxin in clinical medicine, Panorama Community Hospital, Panorama City, California, September 1993

Uses of botulinum toxin in clinical medicine, Huntington Memorial Hospital, Pasadena,

California, September 1993

Clinical use of botulinum toxin, Century City Hospital, Los Angeles, California, September 1993

Clinical use of botulinum toxin, Garfield Medical Center, Alhambra, California, October 1993

Uses of botulinum toxin in clinical medicine, Suburban Medical Center, Paramount, California, November 1993

Parkinson's disease update, Mullikan Medical Group, Glendale, California, March 1994

Tourette's syndrome, North Hollywood Medical Center North Hollywood, California, September 1994

Parkinson's disease update, Valley Hospital, Van Nuys, California, September 1994

Laryngeal dystonia, USC University Hospital, Los Angeles, California, May 1998

Treatments of Parkinson's disease, Citrus Valley Medical Center, Covina, California, March 1999

Parkinson's disease overview, Valley Presbyterian Hospital, Van Nuys, California, October 1999

Treatment of movement disorders with botulinum toxin, San Diego Rehabilitation Institute, San Diego, California, February 2000

New advances in the treatment of Parkinson's disease, Novartis Pharmaceuticals Corporation Neurology Clinical Forum, Denver, Colorado, September 2000

New advances in the treatment of Parkinson's disease. Novartis Pharmaceuticals Corporation Neurology Clinical Forum. Challenges in Neuroscience: The science of Parkinson's disease, Alzheimer's disease, and Epilepsy. Portland, Oregon, September 2000

New treatments for Parkinson's disease, Clinical Update in Neurology: Beyond the Decade of the Brain, Santa Barbara, California, November 2000

Movement disorders, an update and case presentations, Los Angeles, California, November 2000

New treatments for Parkinson's disease, Prescription Solution, Costa Mesa, California, November 2000

Botulinum toxin type B for the treatment of torticollis, University of Texas, Southwestern Medical Center, Dallas, Texas, November 2000

Parkinson's and other movement disorders, 27th annual common problems in primary care-2001, University of Southern California, Los Angeles, California, March 2001

The use of Botulinum toxins in the treatment of Movement Disorders, Clinical Neurology Update 2002, U.S. Army Medical Department, San Antonio, Texas, November 2002

Treatment of Early Parkinson's Disease with Rasagiline: Long term management. Cordoba, Spain. June 2006

New Therapies in PD. Grand Rounds Department of Neurology Cedars Sinai Hospital December 2007

Clinical uses of botulinum toxins above the clavicles. Southern California Kaiser Permanente Group Annual Head and Neck Cancer Symposium April 2008

Botulinum Toxins in Otolaryngology. Grand Rounds Dept of Otolaryngology, Keck/USC School of Medicine May 2008

New Therapies in PD Grand Rounds UNLV School of Medicine June 2009

Treatment of Early PD Grand Rounds Kaiser Sunset Dept Neurology January 2010

A review of Movement Disorders UNLV School of Medicine November 2010

D. SOCIETY MEMBERSHIPS

Fellow, American Academy of Neurology

The Movement Disorders Society

American Academy of Neurology
Movement Disorders Section

European Federation Neurological Sciences

E. RESEARCH ACTIVITIES

Major Areas of Research Interest

Parkinson's disease: Experimental therapies
Treatment of dystonias with botulinum toxins

Research Grants

Site Principal Investigator:

A double-blind, parallel group, placebo controlled study which evaluates the safety, tolerability, and efficacy of Pramipexole in untreated Parkinsonism (STEP-UP). The

Upjohn Company, 02/15/94 – 02/15/95

A phase III multicenter study to evaluate the efficacy and safety of Entacapone, compared with placebo, in the treatment of Parkinson's disease with motor fluctuation (SEESAW). Parkinson Study Group (PSG), 04/01/94 – 06/30/96

Long-term safety study of open-label Pramipexole in early Parkinson's disease (STEP-UP). The Upjohn Company, 07/1/94 – 07/1/98

A double-blind, placebo-controlled, single treatment, dose-finding, safety, tolerability and preliminary efficacy study of Botulinum Toxin Type B at various doses in patients with idiopathic cervical dystonia. Athena Neurosciences, 09/1/95 – 03/1/96

A randomized double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and dosing of Botulinum Toxin Type A purified neurotoxin complex for the treatment of lower limb spasticity in the chronic phase of stroke rehabilitation. Allergan, 11/1/96 – 03/1/98

Early vs. late L-dopa in Parkinson's disease. Stanley Fahn, MD, Principal Investigator. National Institutes of Health, 01/01/97 – 12/31/00

A double-blind, placebo-controlled, single dose, safety and efficacy study of BotB (botulinum toxin type B) in patients with cervical dystonia. Athena Neurosciences, 05/28/97 – 06/1/98

A double-blind, placebo-controlled, single dose, safety and efficacy study of BotB (botulinum toxin type B) in Type A-resistant patients with cervical dystonia. Athena Neurosciences, 05/27/97 – 06/1/98

A multicenter, double-blind, placebo-controlled, parallel group, dose ranging study for the safety, tolerability, efficacy of daily, oral doses of Remacemide Hydrochloride in Parkinson's disease subjects with motor fluctuations. Astra-Merck Pharmaceuticals, 05/29/97 – 06/1/98

A multicenter, double-blind, placebo-controlled, parallel group, Phase III clinical trial for the efficacy, tolerability and safety of two doses of Rasagiline Mesylate (study drug) in early untreated Parkinson's disease (PD) patients not treated with Levodopa. Teva Pharmaceuticals, 05/1/97 – 10/31/99

Genetic linkage study in Parkinson's disease. Richard Hepworth Myers, MD, Principal Investigator. National Institutes of Health, 06/01/97 – 06/01/02

A prospective, randomized, parallel-group, double-blind placebo-controlled, multi-center study to evaluate the short term efficacy and safety of entacapone administered together with levodopa in subjects with Parkinson's disease without motor fluctuations.Novartis Pharmaceuticals, 08/97 – 06/30/00

An open label safety study of NEUROBLOC™ (botulinum toxin type B) in patients with cervical dystonia. Athena Neurosciences, 10/13/97 – 06/15/00

A phase III, multi-center, prospective, randomized, double-blind, placebo controlled study of the efficacy and safety of Dysport for the treatment of cervical dystonia. Ipsen Limited, 04/1/98 – 02/1/00

A randomized, double-blind, parallel-group study to compare the safety and efficacy of Zydis Selegiline 1.25 mg to 2. 5mg with placebo as an adjunct in the management of parkinsonian patients being treated with levodopa who exhibit deterioration in the quality of their response to this therapy. Scherer DDS 05/1/98 – 06/30/00

An open extension study of the safety and efficacy of Zydis selegiline 1.25 to 2.5mg qd as an adjunct in the management of Parkinsonian patients being treated with levodopa. Scherer DDS, 05/1/98- 6/2001

A 12 week, double-blind, placebo-controlled, parallel group, multicenter, exploratory study of the safety and efficacy of KW-6002 as adjunctive therapy in patients with Parkinson's disease who have motor response complications. Kyowa Pharmaceuticals, 09/1/99 – 03/30/00

A single center, double-blind, placebo controlled, dose-escalation study to assess the safety and tolerability of transdermal doses of SPM 962 in subjects with early stage Parkinson's disease. Schwarz Pharma, Inc., 09/16/99 – 06/30/00

A Phase III Multicenter, Double Blind, Parallel-Group PlaceboControlled Study of the effect of Riluzole 50 mg BID or 100 mg BID for Two Years on the Progression of Parkinson's Disease in 1050 Patients. Rhone Poulnec-Rorer, 6/99 to 6/02

PNU-95666E: Open-label, long term, flexible dose study of safety, tolerability, and therapeutic response in patients with Parkinson's disease. Pharmacia, 01/31/00 – 12/31/03

PNU-95666E: A double-blind, placebo-controlled, dose-response study of tolerability, safety and efficacy in patients with early Parkinson's disease. Pharmacia, 02/01/00 – 05/31/00

Roche sample repository research project in association with patients formerly enrolled in Tasmar studies. Hoffmann-La Roche, 04/00-07/00

A multicenter, U.S. and Canada, double-blind, randomized, placebo controlled, parallel-group study for the efficacy, tolerability and safety of Rasagiline Mesylate in Parkinson's disease patients with motor fluctuations (Presto), University of Rochester/Teva, 06/13/00- 07/31/02

Randomized double-blind, placebo-controlled, parallel-group, six-month safety, efficacy, and neuroimaging trial of AMG-474-00 in the treatment of patients with Parkinson's disease Amgen Inc., 07/00-04/01

A single and multiple oral dose safety, tolerance and preliminary efficacy study in Parkinson's disease patients with dyskinesias. Pharmacia, 10/31/00- 4/01

AN072-401CD: An open label safety and immunogenicity study of Myobloc™ (Neurobloc®; Botulinum toxin type B) injectable solution inpatients with cervical dystonia. Elan Pharmaceuticals, 06/01- 07/06

Skye-2004C/101468/167: A phase II, randomized, double-blind, active-controlled, study to determine the optimal initial titration regimen of ropinirole CR tablets in Parkinson's disease patients not receiving other dopaminergic therapies. SkyePharma Inc., 07/01- 12/02

An active extension of the TVP-1012/133 PRESTO study. A bi-national multicenter,double-blind, randomized study to evaluate the safety and tolerability of rasagiline mesylate in advanced Parkinson's disease (PD) patients with motor fluctuations treated with chronic levodopa/carbidopa therapy (Protocol TVP1012/135) Teva Neuroscience LLC., 08/01 – 07/04

Development and Testing of the PTWIST: The Cervical dystonia Patient Self Report Scale. Elan Pharmaceuticals Inc., 10/01 –

Medical Index for Neuromuscular Data (MIND) Registry. Elan Pharmaceuticals Inc., 10/01 – 10/05

SP650: A multicenter, multinational, phase III, randomized, double-blind, parallel group, placebo controlled trial of the efficacy and safety of the rotigotine CDS patch (2 target doses) in subjects with advanced stage idiopathic Parkinson's disease who are not well controlled on levodopa (Part I) and open-label extension to assess the safety of long-term treatment of rotigotine CDS (Part II). Schwarz Biosciences, 07/02-07/04

Skye-2004C/101468/196: A long-term, open-label continuation study of once daily administration of ropinirole CR tablets to patients with Parkinson's disease who completed the previous phase II ropinirole CR study 167. SkyePharma Inc., 07/02- 07/04

Neuroprotective clinical studies in Parkinson's disease. Mark Lew, MD, Principal Investigator, National Institutes of Health NINDS, 09/15/02-8/31/07

ELC200AUS02: A 4 week, multicenter, open label, single arm study assessing tolerability of triple combination (TC) in Parkinson's disease patients who experience end of dose wearing off with levodopa. Novartis Pharmaceuticals Corp., 02/03-06/04

A phase 2, double-blind, dose-finding, placebo-controlled study to assess the efficacy and safety of SCH 420814 as monothrapy in subjects with early Parkinson's disease. Shering Plough 02/03-03/04

EP002: A survey to assess the incidence and characteristics of melanoma in Parkinson's disease (PD) patients. Teva Neuroscience, 04/03-03/04

GSK228: A phase IIIb, randomized, multi-center, double-blind, sinemet-controlled, parallel group, flexible dose study to assess the effectiveness of ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesias in Parkinson's disease while adequately controlling PD symptoms. Glaxo Smith Kline, 05/04-05/06

EMR 62-225-019: A double-blind, placebo-controlled, multicenter, multinational phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 2)
Merck KgaA, 11/01/04-12/31/05

Y-47-52120-051- A Phase III multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of Dysport for the treatment of cervical dystonia. Biomeasure Inc./Ipsen, Ltd. 10/05- 10/06

248-538: A two year open label, randomized, parallel group, blinded assessment ophthalmologic safety study of pramipexole IR versus ropinirole in early Parkinson's disease patients. Boehringer Ingelheim 05/2005 – 04/2007

EMD 62-225-030: An open-label, multicenter, multinational phase II follow-up study to investigate the long-term safety and efficacy of Sarizotan HCI mg b.i.d. in patients with Parkinson's disease (Paddy O). Merck KgaA/Monitoring Force, 06/05-05/08.

SP650: A multicenter, multinational, phase III, randomized, double-blind, parallel group, placebo controlled trial of the efficacy and safety of the rotigotine CDS patch (2 target doses in subjects with advanced stage idiopathic Parkinson's disease who are not well controlled on levodopa (Part I) and open-label extension to assess the safety of long-term treatment of rotigotine CDS (Part II). Schwarz Biosciences, 07/02-07/08

Skye-2004C/101468/196: A long-term, open-label continuation study of once daily administration of ropinirole CR tablets to patients with Parkinson's disease who completed the previous phase II ropinirole CR study 167. Skye Pharma Inc., 07/02-2009

Y-47-52120-731: A Phase III Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport Intramuscular Injection of Cervical Dystonia. Biomeasure Inc./Ipsen, Ltd. 4/06-4/08

PT-ST-01 A phase I, single dose, double blind, placebo controlled, dose escalation study to evaluate the safety of PurTox for the treatment of adult onset spasmodic torticollis/cervical dystonia and to explore dose-associated efficacy. Mentor 2008

A Randomized Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1, 3 and 6 mg Twice Daily) in Patients with Early Parkinson Disease (Aplindore-211) APLIED study. University of Rochester/Neurogen 10/1/08-10/31/09

Active/ 2010 Funded Trials

Principal Investigator: Lew

Active

A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects with Treated Parkinson's Disease (PD). Long-term Study – 1 1 U10 NS44462-02NINDS - NIH 10/26/2006 – 11/00/2010

Randomized, double-blind, parallel group, placebo controlled safety, tolerability and efficacy study of NP002 in subjects with idiopathic Parkinson's disease with dyskinesias due to levodopa therapy Neuraltus pharmaceuticals, Inc 11/25/2009 – 10/26/2010

A Phase 3, Double-Blind, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease Schering Plough P05664 10/18/2010 – 11/00/2011

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the

Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Allon Pharmaceuticals AL-108-231 09/01/2010 – 08/01/2012

Open-Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies Solvay Pharmaceuticals S187.3.005 05/10/2010 - ongoing

An Open-Label, 12 Months Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations Despite Optimized Treatment with Available Parkinson's Disease Medications Solvay Pharmaceuticals S187.3.004 07/23/2008 – 06/00/2011

A two year open label, randomized, parallel group, blinded assessment ophthalmologic safety study of pramipexole IR versus ropinirole in early Parkinson's disease patients. Boehringer Ingelheim 248-538: 05/05 – 12/10

Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease Addex Pharma SA January 2011-

A Phase 3, Randomised, Double Blind And Open Label Phase, Active And Placebo Controlled Study Comparing The Short Term Efficacy Of Two Formulations Of Clostridium Botulinum Type A Toxin (Dysport And Dysport Ru) To Placebo, And Assessing The Short And Long Term Efficacy And Safety Of Dysport Ru Following Repeated Treatments Of Subjects With Cervical Dystonia (Cd) Y-52-52120-134 Ipsen January 2011-

Foundation Grants

HollyRod Foundation, 04/02 –

National Parkinson's Foundation Grant 10/2010-

Co-Investigator:

Active

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study TVP-1012/501 09/25/2009 – 09/00/2011

Randomized, double blind, placebo-controlled, dose ranging trial of oral inosine to assess safety and ability to elevate urate in early Parkinson's disease. Michael J. Fox Foundation/Massachusetts General Hospital 10/01/2010 – 03/00/2012

A longitude observational follow-up of the PRECEPT study cohort (PostCept 413351-G University of Rochester/NIH 09/01/2005 – 12/31/2010

A randomized, double-blind, placebo-controlled, dose-ranging trial of oral inosine to assess safety and ability to elevate urate in early Parkinson's disease (SURE PD) INO-PD-P2-2008 10/01/2010 – 03/00/2012

Evaluation of Blood Biospectroscopy as a novel diagnostic test for idiopathic Parkinson's disease (PD Biospec) SPIN PD Parkinson's Study Group

Co-Investigator:

Novartis Pharmaceuticals 01/31/05 -03/31/08
CELC200A2401/2939107: A long term, double-blind, randomized, parallel-group, carbidopa/levodopa-controlled, multi-center study to evaluate the effect of Stalevo™ in patients with Parkinson's disease requiring initiation of levodopa therapy (Stride PD)PI: Hui
Role: Lew, Co-Investigator (2%) $58,212

Teva Neuroscience 3/06-6/30/08
TVP1012/500 A multicenter, double blind, randomized start, placebo controlled, parallel group study to assess rasagiline as a disease midifying therapy in early Parkinson's disease subjects. (Adagio) PI: Togasaki
Role:Lew, Co-Investigator (2%). $59,154

Kyowa Pharmaceutical 7/18/06-11/30/08
KW6002-US-025 An open label multicenter study of the continued safety of Istradefylline in subjects with Parkinson's disease who have recently completed one year treatment with Istradefylline. PI: Hui
Role: Lew, Co Investigator (2%). Direct Funds: $24,010

Eisai Medical Research Inc.1/1/07-2/1/08
E2007-A001-302 A multicenter, randomized, double blind, placebo controlled, parallel group study of the efficacy, safety and tolerability of E2007 in levodopa treated Parkinson's disease patients with motor fluctuations. PI: Togasaki
Role: Lew, Co-Investigator (2%). Direct Funds: $53,352

Eisai Medical Research Inc. 06/0107-12/01/08
E2007-G000-303 A multicenter, open label extension study to evaluate the long term safety, tolerability and efficacy of E2007 as an adjunctive therapy in levodopa treated Parkinson's disease patients with motor fluctuations. PI: Togasaki
Role: Lew, Co-Investigator (2%). Direct Funds: $53,420

Shering Plough 10/1/07-9/30/08
P 04501- A phase II, 12 week, double-blind, dose-finding, placebo controlled study to assess the efficacy and safety of a range of SCH 420814 doses (1 mg bid, 2 mg bid, 5 mg bid, and possibly 10 mg bid) in subjects with moderate to severe Parkinson's disease experiencing motor fluctuations and dyskinesias. PI: Togasaki
Role: Lew, Co-Investigator (2%). Direct Funds $57,125

Ropinirole 0.5 mg bid, 1.0 mg bid or 2.0 mg bid versus placebo as adjunct to L-Dopa in the treatment of Parkinson disease. SmithKline Beecham Pharmaceuticals, 10/01/91-10/31/92
An open label extension study of Ropinirole as adjunct to L-Dopa (DCI) in the treatment of

Parkinson's disease. SmithKline Beecham Pharmaceuticals, 04/01/92 - 03/31/94

A double-blind placebo controlled parallel group study of oral doses of Ropinirole for six months treatment of early Parkinsonian patients not treated with L-Dopa. SmithKline Beecham Pharmaceuticals, 10/01/92 – 03/31/93

A randomized, double-blind, multicenter study comparing Midodrine (10mg) versus placebo in patients with neurogenic orthostatic hypotension. Roberts Pharmaceuticals, 10/15/92 - 04/15/93.

A double blind placebo controlled parallel group study of oral doses of Ropinirole for six months treatment adjunct therapy in Parkinson patients not optimally controlled on L-Dopa (DCI). Smith Kline Beecham Pharmaceuticals, 10/25/92 - 04/25/93

A placebo-controlled study of the safety and efficacy of cabergoline in the treatment of Parkinson's disease. Adria Pharmaceuticals, 11/01/92 - 10/31/93.

Double blind, placebo controlled parallel group multicenter, dose-finding evaluation of R0-40-7592 in Parkinsonian patients under chronic treatment with Sinemet (levodopa/carbidopa) and presenting with end of dose wearing off. Hoffman LaRoche, 04/01/93 - 06/30/96

Double-blind, placebo controlled, parallel group comparison to assess the safety, tolerance and efficacy of Pramipexole (0679) in advanced Parkinson's disease and to assess long term safety with open label Pramipexole (0979). Boehringer-Ingelheim Pharmaceuticals, Inc. 05/01/93 - 05/01/99

A double blind, placebo controlled six month extension study 1014581055 to evaluate the long term efficacy and safety of Ropinirole in early Parkinsonian patients not receiving dopaminergic therapy. SmithKline Beecham Pharmaceuticals. 05/15/93-05/15/94

A double blind, placebo controlled extension study of Ropinirole as adjunct to L-Dopa in the treatment of Parkinson's disease. SmithKline Beecham Pharmaceuticals. 05/15/93 - 05/15/94

Long-term use of Cabergoline in patients who have completed Phase III Efficacy Study. Adria Pharmaceuticals. 07/01/93- 07/15/97

Evaluation of the efficacy and safety of tolcapone in Parkinson's disease patient with stable response to Sinemet (levodopa/carbidopa). Hoffman LaRoche, 02/01/94 - 06/30/96

A North American open-label long-term safety study on Entacapone in patients with Parkinson's disease. Orion-Farmos, 11/15/94 -11/13/97

A double-blind, placebo-controlled parallel groups, multicenter evaluation of the marketing formulation of Tolcapone when given together with Sinemet (levodopa-carbidopa) to Parkinson's patients who exhibit wearing off. Hoffman-La Roche, 04/1/95 - 10/01/96

Parallel group, double-blind, comparison study of pramipexole and carbidopa-levodopa in the treatment of Parkinson's disease. Pharmacia & Upjohn. 07/15/96 – 08/31/00

A randomized, parallel, study of N-0923 TDS in patients with Parkinson's disease. Discovery Therapeutics, 11/13/96 - 11/13/97

Open label, randomized, parallel group comparison of tolcapone and pergolide given in combination with Madopar (levodopa/ benserazide) or Sinemet (levodopa-carbidopa) in Parkinsonian patients who exhibit end-of-dose "wearing-off" with follow-up extension of Tolcapone. Hoffmann La Roche, 04/97 – 12/98

PNU-95666E: Double blind, placebo controlled, safety, tolerability, pharmacodynamic and pharmacokinetic study of patients with moderate to advanced Parkinson's disease. Pharmacia & Upjohn, 09/97- 04/99

Olanzapine vs. placebo for treatment-associated psychosis in patients with Parkinson's disease. Eli Lilly, 10/97 -10/98

Open label study to identify the reasons for Tasmar dosage regimen changes in fluctuations in Parkinson's disease patient with a follow up extension. Hoffman LaRoche, 10/97 - 12/98

A multicenter, double blind, placebo controlled, parallel group, dose-ranging study for the safety, tolerability and efficacy of SIB-1508Y in PD patients who are requiring but not receiving dopaminergic therapy. Sibia Neurosciences, Inc., 11/97

A long term double-blind comparison of tolcapone vs. placebo given in combination with levodopa/AADC-1 in delaying onset of motor fluctuations in Parkinson's disease patients. Hoffman La Roche, 11/97 - 11/98

A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to assess the efficacy, safety and tolerability of escalating transdermal doses of SPM 963 in subjects with early stage Parkinson's disease (Patch 1). Schwarz Pharma, 09/01/99 – 06/30/00

A multicenter, randomized, double-blind, double dummy, parallel group study comparing TV-1203/carbidopa dispersible tablets with levodopa/carbidopa tablets in advanced Parkinson's disease (PD) patients with motor fluctuations (Rapid). University of Rochester/Schwarz Pharma, 04/00 – 02/28/02

TV-1203/117 - A bi-national, multicenter, open-label study to evaluate the safety and tolerability of TV-1203/carbidopa dispersible tablets in advanced Parkinson's disease (PD) Clinical Research Inc., 05/01-04/04

666E-CNS-0075-021- A phase III, double-blind, placebo-controlled, randomized study comparing the efficacy, safety, and tolerability of Sumanirole versus placebo or Ropinirole in patients with early Parkinson's disease. Pharmacia, 02/02-12/02

SP512- A multicenter, multinational, phase III, randomized, double blind, placebo controlled trial, of the efficacy and safety of the Rotigotine CDS patch in subjects with early stage, idiopathic Parkinson's disease (Part I) and an open label extension to assess the safety of long-term treatment of Rotigotine CDS (Part II). Schwarz Biosciences, 07/02- 07/04

The long term impact of initiating Pramipexole versus levodopa in early Parkinson's disease (The Calm PD Cohort Study). Pharmacia, 7/13/01-8/31/04

A randomized, double blind, placebo-controlled, dose-finding study to assess the efficacy and

safety of CEP-1347 in patients with early Parkinson's disease, PRECEPT. University of Rochester/Cephalon, Inc., 3/1/02-1031/06

6002-US-018: A 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter, fixed dose response study to evaluate the efficacy and safety of 10, 20 and 40 mg/d oral doses of KW-6002 (Istradefylline) as treatment for Parkinson's disease in patients with motor response complications on levodopa/carbidopa therapy Kyowa Pharmaceuticals 12/01/04-12/31/05

6002-INT-001: A long-term, multicenter, open-label safety study oral 20 or 40 mg/d doses of KW-6002 (Istradefylline) as treatment for Parkinson's disease in patients with motor response complications on levodopa therapy.01/10/05-12/31/06

CELC200A2401/2939107: A long term, double-blind, randomized, parallel-group, carbidopa/levodopa-controlled, multi-center study to evaluate the effect of Stalevo™ in patients with Parkinson's disease requiring initiation of levodopa therapy. Novartis Pharmaceuticals 01/31/05 -03/31/08 (Stride PD)

CEPC200AUS11: A prospective, multi-center, randomized, open-label study with blinded raters to evaluate the effects of immediate versus delayed switch to Stalevo® on motor function and quality of life in patients with Parkinson's disease with end of dose wearing off. Novartis Pharmaceuticals 11/11/04- 03/31/06 (Quest)

BIBLIOGRAPHY

Peer Review Articles

1. Moran TH, **Lew MF**, Blass EM: Intracranial self stimulation in three-day-old rat pups. Science 1981; **214**:1366-1368

2. Tune L, Strauss M, **Lew MF**, and Coyle JT: Serum levels of anti-cholinergic drugs and impaired recent memory in chronic schizophrenic patients. American Journal of Psychiatry 1982; **139 (11**):1460-1462

3. Strauss M, **Lew MF**, Coyle JT, Tune LE: Psychological and clinical correlates of attention in chronic schizophrenia. American Journal of Psychiatry 1985; **142 (4)**:497-499

4. DeGiorgio, CM and **Lew, MF**: Consciousness, coma and the vegetative state. Issues in Law and Medicine 1991; **6**:361-372

5. **Lew MF**, Waters C: Clozapine treatment of Parkinsonism with psychosis. Journal of the American Geriatrics Society 1993; **41(6**):669-671

6. **Lew MF**, Shindo M, Moskowitz CB, Wilhelmsen KC, Fahn, S, Waters, CH: Adductor laryngeal breathing dystonia in a patient with Lubag (X-linked dystonia-parkinsonism syndrome). Movement Disorders 1994; **9(3**):318-320

7. Grafton ST, Sutton J, Couldwell W, **Lew M**, Waters C: Network Analysis of motor system connectivity in Parkinson's disease: Modulation of thalamocortical interactions after pallidotomy. Human Brain Mapping 1994; **2**:45-55

8. Sutton JS, Couldwell W, **Lew MF**, Mallory L, Grafton S, DeGiorgio C, Welsh M,

Apuzzo M, Ahmadi J, and Waters C: Venteroposterior medial pallidotomy in patients with advanced Parkinson's disease. Neurosurgery 1995; **36**:1112-1117

9. Grafton ST, Waters CH, Sutton J, **Lew MF**, and Couldwell W: Pallidotomy increases activity of motor association cortex in Parkinson's disease: A Positron Emission Tomographic Study. Annals of Neurology 1995; **37**:776-783

10. **The Parkinson Study Group**: Safety and efficacy of Pramipexole in early Parkinson's disease. JAMA 1997; **278(2)**:125-130

11. **Lew MF**, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, Brin MF, Jankovic J, Rodnitzky RL, Singer C, Swenson MR, Tarsy D, Murray JJ, Koller M, Wallace JD: Botulinum Toxin Type B (BotB): A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia.
Neurology1997; **49**:701-707

12. The Parkinson Study Group (PSG): Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Annals of Neurology 1997; **42(5**):747- 755

13. I.H.Richard, R. Kurlan, C. Tanner, S. Factor, J. Hubble, O. Sucherowsky, C. Waters, and the **Parkinson Study Group** Serotonin Syndrome and the combined use of Deprenyl and an Antidepressant in Parkinson's Disease Neurology 1997;48:1070-1077

14. Adler CH, Singer C, O'Brien C, Hauser RA, **Lew MF**, Marek KL, Dorflinger E,Pedder S, Deptula D
and the Tolcapone Fluctuator Study Group III: Randomized, placebo-controlled study of Tolcapone in patients with fluctuating Parkinson's disease treated with levodopa/carbidopa. Arch Neurology 1998; **55**:1089-1095

15. Brashear A, **Lew MF**, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Willmer-Hulme A, Wallace JD, Koller M: Safety and efficacy of Neurobloc ™ (botulinum toxin type-B) in type-A responsive cervical dystonia patients. Neurology 1999; **53(7**):1439-1446

16. Brin MF, **Lew MF**, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; **53 (7)**:1431-1438

17. **Lew MF,** Brashear A, and Factor S: The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: Summary of three controlled clinical trials. Neurology 2000; **55 (Suppl 5**):S29-S35

18. **Lew MF:** Botulinum toxin type B (Myobloc™): a new choice in cervical dystonia. Expert Rev. Neurotherapeutics 2001; **1 (2**):143-152

19. The Parkinson Study Group (PSG): A randomized controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 2001; **55**:455-462

20. DeStefano AL, Golbe LI, Mark M, Lazzarini AM, Maher NE, Saint-Hilaire MH, Feldman RG, Guttman M, Watts RL, Suchowersky O, Lafontaine AL, Labelle N, **Lew MF,** Waters CH, Growdon JH, Singer C, Currie LJ, Wooten GF, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Stacy M, Montgomery E, MacDonald ME, Gusella JF, Meyers RH. Genome-wide scan for Parkinson's disease: The Gene PD Study. Neurology2001; **57**:1124-1126

21. Maher NE, Golbe LI, Lazzaarini AM, Mark MH, Currie LJ, Wooten GF, Saint-Hilaire M, Wilk JB, Volcjak J, Maher JE, Feldman RG, Guttman M, **Lew M,** Schuman S, Suchowersky O, Lafontaine AL, Labelle N, Vieregge P, Pramstaller PP, Klein C, Hubble J, Reider C, Growdon J, Watts R, Montgomery E, Baker K, Singer C, Stacy M, Myers RH: Epidemiologic study of 203 sibling pairs with Parkinson's disease: The Gene PD Study. Neurology 2002; **58**:79-84

22. DeStefano AL, **Lew MF,** Golbe LI, Mark M H, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF, Maher NE, Wilk JB, Sullivan K, Slater KM, Saint-Hilaire MH, Feldman RG, Suchowersky O, Lafontaine AL, Labelle N, Growdon JH, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Reider CR, Stacy M, MacDonald ME, Gusella JF, Myers RH: PARK3 influences age at onset for Parkinson's disease: A genome scan for onset age in the Gene PD Study. American Journal of Human Genetics 2002; **70**:1089-1095

23. Shults C, Oakes D, Kieburtz K, Beal F, Haas R, Plumb S, Juncos J, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, **Lew M**, Parkinson's Study Group: Effects of CoEnzyme Q10 in early Parkinson's disease- Evidence for slowing of the functional decline. Archives of Neurology 2002; **59(10)**:1541-1550

24. **The Parkinson Study Group** (PSG): A controlled trial of Rasagiline in early Parkinson's disease (The Tempo Study). Archives of Neurology 2002; **59**:1937-1943

25. **Lew M F**: Botulinum toxin type B (Myobloc™): An effective treatment for alleviating pain associated with cervical Dystonia. Journal of Back and Musculoskeletal Rehabilitation 2002; **16**:3-9

26. **Lew MF**: Review of the FDA approved uses of Botulinum toxins, including data suggesting efficacy in
pain reduction. Clinical Journal of Pain 2002; **18 (Suppl 6)**: S142-S146

27. **Lew MF,** Manek S: Gait and balance dysfunction in adults. Current Treatment Options in Neurology 2003; **5 (2)**: 177-185

28. Comella CL, Leurgans S, Wuu J, Stebbins GT, Chumura T, **Dystonia Study Group**: Rating Scales for Dystonia: A multi-center assessment. Movement Disorders 2003; **18 (3)**: 303-312

29. S. Karamohamed, PhD, L.I. Golbe, MD, M.H. Mark, MD, A.M. Lazzarini, PhD, O. Suchowersky, MD, N. Labelle, BN, M. Guttman, MD, L.J. Currie, PhD, G.F. Wooten, MD, M. Stacy, MD, M. Saint-Hilaire, MD, R.G. Feldman, MD, K.M. Sullivan MPH, C.M. Shoemaker, BS, J.B. Wilk, DSc, A.L. DeStefano, PhD, J.C. Latourelle, MS, G. Xu, MS, R. Watts, MD, J. Growdon, MD, **M. Lew**, MD, C. Waters, MD, P. Vieregge, MD, P.P. Pramstaller, MD, C. Klein, MD, B.A. Racette, MD, J.S. Perlmutter, MD, A. Parsian, PhD, C. Singer, MD, E. Montgomery, MD, K. Baker, PhD, J.F. Gusella, PhD, S.J Fink, MD, PhD, R.H. Myers, PhD, A. Herbert, MD, PhD: A haplotype at the PARK3 locus influences onset age for Parkinson's disease: The Gene PD study. Neurology 2003; **61**: 1557 -1561

30. Hauser RA, Hubble JP, Truong DD, **KW-6002 Study Group**: A Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 2003; **61**: 297-303

31. **Parkinson Study Group (PSG)**: A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; **16**: 561 – 566

32. **Parkinson's Study Group (PSG**): Levodopa and the progression of Parkinson's disease. New England J Med 2004; **351**: 2498-2508

33. Daniel Truong, Drake D. Duane, Joseph Jankovic, Carlos Singer, Lauren C. Seeberger, Cynthia L. Comella, **Mark F. Lew,** Robert L. Rodnitzky, Fabio O. Danisi, James P. Sutton, P. David Charles, Robert A. Hauser and Geoffrey L. Sheean: Efficacy and safety of botulinum type A toxin (Dysport®) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study. Movement Disorders 2004; **20(7)**: 783-791

34. S. Karamohamed, PhD, L.I. Golbe, MD, M.H. Mark, MD, A.M. Lazzarini, PhD, O. Suchowersky, MD, N. Labelle, BN, M. Guttman, MD, L.J. Currie, PhD, G.F. Wooten, MD, M. Stacy, MD, M. Saint-Hilaire, MD, R.G. Feldman, MD, C.M. Shoemaker, BS, J.B. Wilk, DSc, A.L. DeStefano, PhD, J.C. Latourelle, MS, G. Xu, MS, R. Watts, MD, J. Growdon, MD, **M. Lew**, MD, C. Waters, MD, P. Vieregge, PhD, P.P. Pramstaller, MD, C. Klein, MD, B.A. Racette, MD, J.S. Perlmutter, MD, A. Parsian, PhD, C. Singer, MD, E. Montgomery, MD, K. Baker, PhD, J.F. Gusella, PhD, A. Herbert, MD, PhD and R.H. Myers, PhD.: Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from Gene PD. Movement Disorders 2005 **20(9):** 1188-1191

35. **Mark F. Lew:** Selegiline orally disintegrating tablets for the treatment of Parkinson's disease. Expert Review in Neurotherapeutics 2005 **5(6):** 705-712

36. Karamohamed S, Latourelle JC, Racette BA, Perlmutter JS, Wooten GF, **Lew MF**, Klein C, Shill H, Globe LI, Mark MH, Guttman M, Nicholson G, Wilk JB, Saint-Hilaire MH, DeStefano Al, Prakash R, Williamson S, Tobin J, Suchowersky O, Chinnery PF, Sherman S, Vieregge P, Litvan I, Gusella JF, Myers RH, Parsian A: BDNF genetic variants are associated with onset-age of familial Parkinson's disease: Gene PD study. Neurology. 2005;65(11):1823-5

37. Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC,Kieburtz K**; NET-PD Investigators**. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb;57(2):197-203.

38. L. Elmer, S. Schwid, S. Eberly, C. Goetz, S. Fahn, K. Kieburtz, D. Oakes, K. Blindauer, P.Salzman, S. Oren, U.L. Prisco, M. Stern, I Shoulson, Parkinson Study Group and **Tempo and Presto Investigators** Journal of Neurological Sciences 248 (2006) 78-83

39. The Parkinson's Study Group **Net PD Investigators**: A randomized, double-blinded, futility clinical trial of creatine and minocycline in early Parkinson's disease. Neurology 2006;66 664-671

40. The Parkinson's Study Group **Net PD Investigators**: Using futility designs in Parkinson's disease to optimize the ongoing search for new treatments. Neurology 2006;66 628-633

41. Christopher G. Goetz, MD, Steven R. Schwid, MD, Shirley W. Eberly, MS, David Oakes, Phd, Ira Shoulson, MD and the **Parkinson Study Group TEMPO and PRESTO investigators**: Safety of rasagiline in elderly Parkinson's disease patients. Neurology. 2006 ;66(9):1427-9.

41. M. Sun, MD, PhD, J.C. Latourelle, MS, G.F. Wooten, MD, **M.F Lew, MD,** C. Klein, MD, H. Shill, MD, L.I. Golbe, MD, M.H. Mark, MD, B.A. Racette, MD, S. Perlmutter, MD, A. Parsian, PhD, M Guttman, MD, G. Nicholson, PhD, G. Xu, MS, J.B. Wilk, DSc, M. Saint- Hilaire, MD, A.L DeStefano, PhD, R. Prakash, S. Williamson, O. Suchowersky, MD, N. Labelle, BN, J. Growdon, MD, C. Singer, MD, R.L. Watts, MD, S. Goldwurm, MD, G.Pezzoli, MD, K.B. Baker, PhD, P.P. Pramstaller, MD, D.J. Burn, MD, P.F. Chinnery, MD, S. Sherman, MD, P. Viergge, PhD, I. Litvan, MD, T. Gillis, BS, M.E. MacDonald, PhD, R.H. Meyers, PhD, J.F. Gusella, PhD: Heterozygosity for Parkin mutation influences onset age in familial Parkinson's disease: The Gene PD Study. Arch Neurol. 2006 Jun;63(6):826-32

42. Wilk JB, Tobin JE, Suchowersky 0 , Shill HA, Klein C, Wooten GF, **Lew MF** et al "Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: The *Gene*PD Study Neurology 2006; 67:2206-2210

43. The NINDS **NET-PD Investigators**. A Randomized Clinical Trial of Coenzyme Q10 and GPI- 1485 in Early Parkinson's Disease. Neurology 2007; 68;20-28

44. **Mark F. Lew,** Rajesh Pahwa, Maureen Leehey, John Bertoni , Greg Kricorian and the Zydis Selegiline Study Group. Safety and efficacy of selegiline orally disintegrating tablets as an adjunct to levodopa in the management of "off" episodes in patients with Parkinson's disease. Current Medical Research and Opinion 2007 23 (4) 741-750

45. K Wirdefeldt, M Gatz, S Bakaysa, A Fiske, M Flensburg, G Petzinger, H Widner**, M Lew**, M Welsh, N Pedersen Complete Ascertainment of Parkinson disease in the Swedish Twin Registry. Neurobiol Aging. 2008 Dec;29(12):1765-73

46. Results From a 2-Year Centralized Tolcapone Liver Enzyme Monitoring Program,

Mark F. Lew, Greg Kricorian Clinical Neuropharmacology 2007 30(5) 281-286

47. Overview of Parkinson's Disease, **Mark F. Lew**, Pharmacotherapy 2007 27(12

48.Rasagiline for the Management of Parkinson's Disease. **Mark F. Lew** Therapy 2008 5(2) 203-214

49. Role of Botulinum Toxin in Cervical Dystonia. Eric Molho, Joseph Jankovic, **Mark Lew** . Neurologic Clinics 2008;(Suppl 1) 43-53

50 J.E. Tobin, PhD, J.C. Latourelle, MS, **M.F. Lew**, MD, C. Klein, MD, O. Suchowersky, MD, H.A. Shill MD, L.I. Golbe, MD, M.H. Mark, MD, J.H. Growdon, MD, G.F. Wooten, MD, B.A. Racette, MD, J.S. Perlmutter, MD, R. Watts, MD, M. Guttman, MD, K.B. Baker, PhD, S. Goldwurm, MD, G. Pezzoli, D, C. Singer, MD, M.H. Saint-Hilaire, MD, A.E. Hendricks, BA, S. Williamson, BS, M.W. Nagle, BA, J.B. Wilk, DSc, T. Massood, BS, J.M. Laramie, PhD, A.L. DeStefano, PhD, I. Litvan, MD,G.Nicholson, MD, A. Corbett, MD, S. Isaacson, MD, D.J. Burn, MD, P.F. Chinnery, MD, P.P. Pramstaller, MD, S. Sherman, MD, J. Al-hinti, MD, E. Drasby, MD, M. Nance, MD, A.T. Moller, MD, K. Ostergaard, MD, PhD, R. Roxburgh, PhD, B. Snow, MD, J.T. Slevin, MD, F. Cambi, MD, J.F. Gusella, PhD, R.H. Myers, PhD Haplotypes and gene expression implicate the *MAPT* region for Parkinson disease: The *Gene* PD Study Neurology 2008;71:29-35

51. Christopher F. McNicoll, BA, Jeanne C. Latourelle,MS, Marcy E. MacDonald PhD, **Mark F. Lew, MD**, Oksana Suchowersky, MD, Christine Klein, MD, Lawrence . Golbe, MD,8Marjorie H. Mark, MD, John H. Growdon, MD, G. Fredrick Wooten, MD, Ray L. Watts, MD, Mark Guttman, MD, Brad A. Racette, MD, Joel S. Perlmutter, MD, Anwar Ahmed, MD, Holly A. Shill, MD, Carlos Singer, MD, Stefano Goldwurm, MD, Gianni Pezzoli, MD,16 Marie H. Saint-Hilaire, MD, Tiffany Massood, BS, Karen W. Huskey, BA, Anita L. DeStefano, PhD, Kenneth B. Baker, PhD, Ilia Itin, MD, Irene Litvan, MD, Garth Nicholson, MD, Alastair Corbett, MD, Martha Nance, MD, Edward Drasby, MD, Stuart Isaacson, MD, David J. Burn, MD, Patrick F. Chinnery, MD, Peter P. Pramstaller, MD, Jomana Al-hinti, MD, Anette T. Moller, MD, Karen Ostergaard, MD, PhD, Scott J. Sherman, MD, Richard Roxburgh, PhD, Barry Snow, MD, John T. Slevin, MD, Francis Cambi, MD, James F. Gusella, PhD, Richard H. Myers, PhD Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD Study Mov Disorders 2008 23(11)1596-1601

52. William B. White, M.D., Phyllis Salzman, Ph.D., Steven R. Schwid, M.D. and **The Parkinson Study Group Presto Investigators**. Transtelephonic Home Blood Pressure To Assess The Selective Monoamine Oxidase-B Inhibitor Rasagiline In Parkinson Disease. Hypertension 2008;52: 587-593

53. Anita L. DeStefano PhD, Jeanne Latourelle ,MS, **Mark F. Lew, MD**, Oksana Suchowersky, MD, Christine Klein, MD, Lawrence I. Golbe, MD, Margery H. Mark, MD, John H. Growdon, MD, G. Fredrick Wooten, MD, Ray Watts, MD, Mark Guttman, MD, Brad A. Racette, MD, Joel S. Perlmutter, MD, Lynn Marlor, BSN, MSHS, Holly A. Shill, MD Carlos Singer, MD, Stefano Goldwurm, MD, Gianni Pezzoli MD, Marie H. Saint-Hilaire, MD, Audrey E. Hendricks, BA, Adam Gower,MS, Sally Williamson, BS, Michael W. Nagle, BA, Jemma B. Wilk, DSc, Tiffany Massood, BS, Karen W. Huskey, BA, Kenneth B. Baker, PhD, Ilia Itin, MD, Irene Litvan, MD, Garth Nicholson, MD, Alastair Corbett, MD, Martha Nance, MD, Eward Drasby, MD, Stuart Isaacson, MD, David J. Burn, MD, Patrick F. Chinnery, MD, Peter P. Pramstaller, MD, Jomana Al-hinti, MD, Anette T. Moller, MD, Karen Ostergaard, MD, PhD, Scott J. Sherman, MD, Richard Roxburgh, PhD,

Barry Snow, MD, John T. Slevin, MD, Franca Cambi, MD, James F. Gusella, PhD, Richard H. Myers, PhD Replication of association between *ELAVL4* and parkinson Disease; The *Gene*PD Study. Human Genetics (2008) 124:95–99

54..The NINDS **Net-PD Investigators**.A pilot clinical trial of creatine and minocycline in early Parkinson's disease:18- month results. Clinical Neuropharmacology 2008;31: 141-50

55. Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S; Parkinson Study Group **ELLDOPA Investigators**. Fatigue in levodopa-naive subjects with Parkinson disease.Neurology. 2008 Aug 12;71(7):481-5

56.Latourelle JC, Sun M, **Lew MF**, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, Destefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's Disease: the GenePD study.BMC Med. 2008 Nov 5;6(1):32.

57. Nathan Pankratz · Jemma B. Wilk · Jeanne C. Latourelle · Anita L. DeStefano · Cheryl Halter · Elizabeth W. Pugh · Kimberly F. Doheny · James F. Gusella · William C. Nichols · Tatiana Foroud · Richard H. Myers · The PSG—PROGENI and **GenePD Investigators**, Coordinators and Molecular Genetic Laboratories Genomewide association study for susceptibility genes contributing to familial Parkinson disease Hum Genet. 2009 Jan;124(6):593-605. Epub 2008 Nov 6.

58. G. Schifitto, J. H. Friedman, D. Oakes, L. Shulman, C. L. Comella, K. Marek, S. Fahn and **The Parkinson Study Group ELLDOPA Investigators** Fatigue in levodopa- naïve subjects with Parkinson disease *Neurology* 2008;71;481-485

59. Robert A. Hauser, MD' **Mark F. Lew, MD**; Howard I. Hurtig, MD; William G. Ondo MD, Joanne Wojcieszek, MD; Cheryl J. Fitzer-Attas, PhD; on behalf of the TEMPO Open-label Study Group Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009 Mar 15;24(4):564-73.

60. Jack J Chen, PharmD, BCPS, CGP, FASCP, **Mark F Lew, MD**, Andrew Siderowf, MD, MSCE Strategies and Quality of Care Indicators for Patients with Parkinson's Disease. Journal of Managed Care Pharmacy 2009;15(3)(Suppl):S1-S21

61. Latourelle J.C., Pankratz N et al and the **Gene PD Investigators**. Genomewide association study for onset age in Parkinson's Disease. *BMC Medical Genetics* 2009, **10**:982

62. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T, Myers RH; PSG-PROGENI and **GenePD Investigators**, Coordinators and Molecular Genetic Laboratories.Genomewide association study for susceptibility genes contributing to familial Parkinsons disease.Hum Genet. 2009 Jan;124(6):593-605

63. Hauser RA, Auinger P, Oakes D on behalf of the **Parkinson Study Group**. Levodopa response in early Parkinson's disease. *Mov Disord* 2009;24:2328-2336

64. Kelly E. Lyons, PhD, Joseph H. Friedman, MD, Neal Hermanowitz, MD, Stuart H. Isaacson, MD, Robert A. Hauser, MD, Bonnie P. Hersh, MD, Dee E. Silver, James W. Tetrud, MD, Lawrence W. Elmer, MD, Sotirios Parashos, MD, Lynn K. Struck, MD, **Mark F. Lew, MD**, Rajesh Pahwa, MD.Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist Related Adverse Effects. Clin Neuropharmacol 2010 Jan-Feb;33(1):5-10

65 .John M. Bertoni, MD, PhD; John Philip Arlette, MD, FRCPC; Hubert H. Fernandez, MD; Karen Frei, MD; Mark Forrest Gordon, MD; Mohamed N. Hassan, MD, PhD; Stuart H. Isaacson, MD; **Mark F. Lew**, MD; Eric Molho, MD, FAAN; William G. Ondo, MD; Tania J. Phillips, MD; Carlos Singer, MD; James P. Sutton, MD; and John E. Wolf Jr, MD; for the North American Parkinson's and Melanoma Survey Investigators. Increased Melanoma Risk in PD: A Prospective Clinicopathological Study . Arch Neurol. 2010;67(3):347-352

66. **Mark Lew**, Robert Chinnapongse ,Meg Corliss, Yuxing Zhang .RimabotulinumtoxinB Effects on Pain associated with Cervical Dystonia: Results of Placebo and Comparator-Controlled Studies. International Journal of Neuroscience 120,298-300,2010

67. **Mark F. Lew**, Robert A. Hauser,Howard I. Hurtig,William Ondo,JoAnn Wojcieszek, Cheryl Fitzer-Attas,Tamar Goren, Galia Shifroni and the TEMPO Extension Study Group. Long-term Rasagiline as Maintenance Therapy for Parkinson's Disease, International Journal of Neuroscience 120,404-408,2010

68. Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL; **228 Study Investigators**.Onset of dyskinesias with adjunct ropinerole prolonged release or additional levodopa in early Parkinsons disease. Mov Disord. 2010 May 15;25(7):858-66.

69. Elble RJ, Suchowersky O, Shaftman S, Weiner WJ, Huang P, Tilley B**; NINDS NET-PD Investigators.** Impact of belief of neuroprotection on therapeutic intervention in Parkinson's disease.Mov Disord. 2010 Jun 15;25(8):1082-6.

70. Daniel Truong, MD, Matthew Brodsky, **Mark Lew,** Olga Orlova, and Sofia Timerbaeva, on behalf of the Global Dysport Cervical Dystonia Study Group Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun;16(5):316-23

71. Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson's Disease Robert A. Hauser, Heinz Reichmann, Mark Lew, Afsaneh Asgharian, Clare Makumi, Kenneth J Shulman[4] on behalf of The 196 Study Group. In Press 1/2011 International Journal of Neurosciences

Publication/Book Review

1. **Mark F. Lew:** Mental and behavioral dysfunction in Movement Disorders. In: Bedard M-A, Agid y, Chouinard S, Fahn S, Korczyn AD, Lesperance P, Fritz R, eds. Totowa, N.J. Humana Press 2003;Inc. pp 561

Manuscripts Submitted

1. Nagle MW; Latourelle JC, **; Lew MF**, ; Klein C,; Golbe LI, Mark MH, ; Growdon JH, ; Wooten GF,; Watts RL,; Guttman M,; Racette BA,; Perlmutter JS,; Suchowersky O, ; Furtado S,; Saint-Hilaire MH, ; Wilk JB,; Hendricks AE,; Williamson S, Massood T,; DeStefano AL, [3]; Ahmed A, ; Shi; Nance M, Drasby E, ; Isaacson S, Burn DJ, Chinnery PF; Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT; Cambi F; Gusella JF, Myers RH,Polymorphisms and Expression in SIRT3 are associated with Parkinson disease: The Gene PD Study. Submitted Neurology 12/2009

2. Effects of Immediate Versus Delayed Switch From Levodopa/Carbidopa to Levodopa/Carbidopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-Dose Wearing Off Mark F. Lew, MD, FAAN[1], Monique Somogyi, MD[2], Kevin McCague, MA[2], Mickie Welsh, DNSc Submitted International Journal Neurosciences 12 2010

Book Chapters

1. **Lew MF,** Waters CH: Post traumatic movement disorders In: L. Stone, Ed.Physical medicine and rehabilitation: State of the Art Reviews. Philadelphia: Hanley & Belfus, Inc., 1993; **17 (3)**: 517-524

2. **Lew M**: Hemifacial Spasm In: Adler CH, Ahlskog JE, Eds. Parkinson's disease and movement disorders: Diagnosis and Treatment Guidelines for the Practicing Physician. Totowa, NJ: Humana Press Inc. 2000; pp 313-319

3. **Lew MF**: Efficacy of Bont-B in decreasing pain from cervical dystonia In: The management of acute and chronic pain: the use of the "Tools of the Trade". (Krames E, Reig R, Eds) Monduzzi Editore S.p.A. San Francisco, California 2000; pp 451-455

4. Chung JX, Wu AD, **Lew MF:** Amantadine and Anticholinergics In: Marcel Dekker Inc., Eds: Pahwa: Handbook of Parkinson's Disease. Tradespools ltd., Frome, Somerset. 2002; 3rd Edition Chapter 16, pp 4242-4247

5. **Lew MF.** Duration of effectiveness of botulinum toxin type B in the treatment of cervical dystonia. *Advances in Neurology. 94:211-5, 2004.*

6. J Hui, G. Murdock, J Chung, **M Lew:** Behavioral changes as side effects of medication treatment for Parkinson's disease. In: Behavioral Neurology of Movement Disorders. Weiner WJ, Lang AE, and Anderson KE, eds. Philadelphia: Raven Press, 2005.

7. K Dashtipour, **M Lew**: Cervical Dystonia. Chapter 10 ,Handbook of Dystonia, ed M Stacy. Informa Healthcare, NY 2006

8. **Lew, MF**. Focal dystonia in a string musician: a case of mistaken identity In: Movement Disorders: 100 instructive cases, ed S Reich. Taylor and Francis, NY 2006. In Press

9. **Lew MF**, Waters C (Eds). Parkinson's Disease: extending the effectiveness of levodopa through COMT and MAO-B inhibition. London: RSM In Press, 2006.

10. Dashtipour, K , Chung JX, Wu AD, **Lew MF:** Amantadine and Anticholinergics In: Informa Healthcare, Eds: Pahwa: Handbook of Parkinson's Disease.. 2007; 4th Edition Chapter 17, pp 291-305

11. Hui JS and **Lew, MF.** Calcification of the basal ganglia. Handbook of Clinical Neurology, Vol 84 (3rd Series) Parkinson's Disease and Related Disorders. W.C. Koller, E Melamed, Eds . Elsevier BV 2007

. . 12. Marvi, , Michael M. and Lew, Mark F 'Polycythemia and chorea' in Weiner, W. J and Tolosa, E, Hyperkinetic Movement Disorders, Elsevier. (2011) Chapter 19

Abstracts

1. **Lew MF**, Stoloff M, Blass E: Suckling vs. free feeding: Preferences in developing albino rats. Proceedings of the Eastern Psychological Association, 1979

2. **Lew MF**, Moran T, Blass E: Intracranial self stimulation in three-day-old rat pups. Proceedings of the International Society for Developmental Psychobiology, 1980

3. **Lew, MF**, Gibbs J: Gastric inhibitory polypeptide (GIP) suppresses real but not sham feeding in the rat. Proceedings of the Eastern Psychological Association. 1982

4. Gibbs J, **Lew MF**: Intestinal satiety is elicited by L- but not D-Phenylalanine. Proceedings of the Society for Neuroscience, 1983

5. Gibbs J, Jerome C, **Lew MF**: Evidence against the CCK hypothesis: Proglumide does not increase food intake in rats. Proceedings of the IX International Conference of Physiology of Fluid and Food Intake, 1986

6. Hudson M, Cooper C, **Lew MF**, Waters C: Hand therapy following Botulinum toxin injection for severe dystonia of the upper extremity. Journal of Hand Therapy,

7. Askanas V, Alvarez RB, McFerrin J, Serdaroglu P, **Lew MF**, and Engel KW: Facio-scapulo humeral (FSH) syndrome with abnormal desmin accumulation: A new entity? Neurology 1992; **42 (Suppl 3**):229

8. **Lew MF**, and Waters CH: Treatment of parkinsonism with psychosis using clozapine. Movement Disorders 1992; **7(1**):100

9. **Lew MF**, Shindo M, Moskowitz C, Fahn S and Waters CH: Adductor laryngeal "breathing dystonia" in a case of X-linked dystonia-parkinsonism syndrome. Movement Disorders1992; **7(3):**14,

10. **Lew MF**, Grafton S, Shindo M, Conti P, Waters CH: ^{18}Fluorodeoxyglucose positron emission tomography scanning in spasmodic dysphonia pre and post Botox™. Movement Disorders 1993; **8(3):** 413

11. Welsh MD, Cymerman J, **Lew MF**, Waters CH: Illness impact and psychosocial adjustment: A psychometric study of patients with dystonia. Movement Disorders 1994; **9(4**):18

12. **Lew MF**, Wilson BA, deLeon D, Waters CH: Seventy-six-year-old twins with dystonia. Movement Disorders1994; **9(4**):18

13. Grafton ST, Couldwell W, **Lew MF**, Sutton J, Waters CH: Pallidotomy increases movement related activity in motor cortical areas in Parkinson's disease: A PET activation study. Ann Neurol 1994; **30**:315

14. Sutton JP, Couldwell W, **Lew MF**, Mallory L, Grafton ST and Waters CH: Ventroposterior medial pallidotomy in patients with advanced Parkinson's disease. Neurology 1994; **44 (Suppl 2):**A304

15. **Lew MF**, Shindo M, Conti P, Waters C, Grafton S: The effects of Botox® injection on ^{18}FDG-PET Scanning in spasmodic dysphonia. Neurology 1994; **44 (Suppl 2)**: A214

16. Welsh MD, Ved N, **Lew MF**: Quality of life in cervical dystonia before and after treatment with botulinum toxin. Movement Disorders 1995; **10(5):**13

17. Abrey LE, **Lew MF**: Oromandibular dystonia following dental manipulation. Movement Disorders 1995; **10(5):**13

18. **Lew MF**, Marton E, Welsh MD: Quality of life outcomes in cervical dystonia before and after botulinum toxin treatment. Neurology1996; **46**: A 260

19. Adler CH, Singer C, **Lew MF**, O'Brien C, Pedder SCJ, Deptula D: Double-blind, placebo-controlled, parallel-groups, multicenter study of Tolcapone (Tasmar®) in Parkinson's disease patients with Sinemet®-induced end-of-dose wearing-off. Neurology 1997; **48**: A 75

20. **Lew MF**, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, Brin, MF, Jankovic J, Rodnitzky RL, Singer C, Swenson MR, Tarsy D, Koller M, Wallace JD: A double-blind, placebo-controlled, single treatment, dose-finding, safety, tolerability and preliminary efficacy study of BotB ™ (botulinum toxin type B) at various doses in patients with idiopathic cervical dystonia. Movement Disorders 1997; **12(3**):33

21. Welsh M, Regalado G, **Lew M**, Waters CH: Reliability and validity of the PPSS: Parkinson's patient motor self-report scale. Movement Disorders **12(5**):844, 1997

22. **Lew M**: A patient with essential tremor developing severe torticollis after bilateral

thalamotomies. Movement Disorders 1997; **12(5**):845

23. Brashear A, **Lew MF**, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of Neurobloc™
(botulinum toxin type-B) in type-A responsive cervical dystonia patients. Neurology 1999; **52(2):**A292,

24. Brin MF, **Lew MF**, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Wilmer-Hulme A, Koller M: Safety and efficacy of Neurobloc™ (botulinum toxin type B) in type A resistant cervical dystonia patients. Neurology 1999; **52(2**): A293

25. **Lew MF**: A patient with idiopathic Parkinson's disease and amyotrophic lateral sclerosis. Movement Disorders 1999; **14:**906

26. Welsh MD, Comella C, **Lew MF**: Quality of life in cervical dystonia: a comparison of the subjective and objective assessments. Movement Disorders 1999; **14**: 902

27. Welsh M, Ganguly G, **Lew M**: Late onset Parkinson's disease in four living siblings. Movement Disorders 2000; 15**(Suppl 3**): P92

28. Factor SA, **Lew MF,** Trosch RM: Current and emerging treatments for cervical dystonia. Medical Broadcast Ltd. (MBL) 2000; Vol**. 5, No.6 (Suppl 5)**

29. The **Parkinson Study Group (PSG**): A controlled trial of Rasagiline in early Parkinson's Disease (The TEMPO Study). Annals of Neurology 2000; **48 (3**):489

30. The **Parkinson Study Group (PSG)**: Tyramine challenge to assess the safety of Rasagiline monotherapy in a placebo-controlled multi-center trial for early Parkinson's disease (The Tempo Study). Neurology 2001; **56 (Suppl 3**):A345

31. Comella C, **Dystonia Study Group**: Rating Scales for dystonia: A multicenter assessment of three dystonia rating scales: The Unified Dystonia Rating Scale (UDRS), the Burke-Fahn-Marsden (BFM), and the Global Dystonia Rating Scale (GDS). Neurology 2001; **56 (Supp 3**): S49-008

32. Kieburtz K, **Parkinson Study Group (PSG**): Efficacy and safety of Rasagiline as monotherapy in early Parkinson's disease. Parkinsonism and Related Disorders 2001; **7 (Supp**): P-TU-200

33. Wright E, Gomez-Mancilla B, Schaaf L J, Bennett J P, Pahwa R, **Lew M F,** Weiner W J, Pfeiffer R: Sumanirole, a new dopamine agonist for the treatment of Parkinson's disease. European Federation of Neurological Studies, 2002

34. Welsh M, Kawai C, Broutman G, Lopez B, **Lew M**: Reliability and validity of the PTWIST: Cervical dystonia patient self-assessment scale. Movement Disorders 2002; **17 (Suppl 5)**: S297

35. Welsh M, Kawai C, Broutman G, **Lew M**: A prospective study of the PPSS:

Parkinson's patient motor self-report scale. Movement Disorders 2002; **17(5**): 1113

36. **M. Lew**, M. Welsh: Dose escalation study assessing the safety and tolerability of Rotigotine constant delivery system in patients with early Parkinson's disease. Movement Disorders 2002; 17**(5):** 1112

37. Troung DD, Comella CL, Danisi F, Jankovic J, Duane DD, **US Dysport Dystonia Study Group**: The efficacy and safety of Dysport (Botulinum type A toxin) in cervical dystonia; results of the first US study. Movement Disorders 2002; **17 (Suppl 5)**: S306

38. **Parkinson Study Group**: Rasagiline improves quality of life in patients with early Parkinson's disease.
Movement Disorders 2002; **17 (Suppl 5):** S92

39. **M.F. Lew**, R. Pahwa,J. Bertoni Long-term efficacy and safety of Zydis Selegiline in Parkinson's disease. Movement Disorders 2004, **19 (Suppl 9) S130**

40. JS Hui, **MF Lew Dopamine** related behavioral disorders in Parkinson's Disease. Movement Disorders 2004, 19 **(Suppl 9) S280**

41. **M. Lew**, R. Hauser, H. Hurtig, W. Ondo, J. Wojcieszek: Long-term efficacy of rasagiline in Parkinson's disease. Movement Disorders 2005 **20 (Suppl 10): S75**

42. R Hauser, **M. Lew**, H. Hurtig, W. Ondo, J. Wojcieszek: Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease. Movement Disorders 2005 **20 (Suppl 10) S75**

43. **M.F. Lew**, G.J. Kricorian: Results from a 2-year centralized tolcapone liver enzyme monitoring program. Movement Disorders 2005 **20 (Suppl 10) S119**

44 Robert Hauser, **Mark Lew**, Howard Hurtig, William Ondo, Joanne Wojcieszek Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease. Neurology 2005 65**(Suppl 1) A107**

45. **Mark Lew**, Robert. Hauser, Howard. Hurtig, William Ondo, Joanne. Wojcieszek: Long-term efficacy of rasagiline in Parkinson's disease. Neurology 2005 65(Suppl 1) A396

46 R Hauser, **M. Lew**, H. Hurtig, W. Ondo, and J. Wojcieszek: Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease. Parkinson's and Related Diseases 2005, **11 (Suppl. 2), 129**

47. **M. Lew**, R. Hauser, H. Hurtig, W. Ondo, J. Wojcieszek: Long-term efficacy of rasagiline in Parkinson's disease. Parkinson's and Related Diseases 2005, **11 (Suppl. 2), 129**

48. R.A. Hauser, **M.F. Lew**, H.J. Hurtig, W. Ondo and J.A.Wojcieszek Early treatment with Rasagiline is more beneficial than delayed treatment starting the long-term management of Parkinson's disease: Analysis of the TEMPO ITT

cohort. European Journal of Neurology 2005 12**(**Suppl 2) SC116

49. **MF Lew**, R.Hauser, H.I. Hurtig, W Ondo, and J.A. Wojcieszek Long-term efficacy of rasagiline in Parkinson's disease patients European Journal of Neurology 2005 12(Suppl 2) SC117

50**.** **Mark F. Lew** Long-term safety and Efficacy of a novel MAO-B inhibitor in the treatment of Parkinson's disease Annals of Neurology 2005 58(Suppl 9) S54

51. **Lew, M**, Kricorian, G Results from a 2 year centralized tolcapone liver enzyme monitoring system. Journal of the Neurological Sciences 2005 238 (Suppl 1) S363

52. **Lew, M,** Kricorian, G Long-Term treatment of Parkinson's disease with a novel MAO-B Inhibitor: Analysis of Safety and Efficacy. Journal of Neurological Sciences 2005 238**(**Suppl 1) S363

53. **Lew, M,** Factor, S. A 4 year observational study of repeated dosing with botulinum toxin type B in patients with cervical dystonia. Neurology 2006 66 **(**Suppl 2) A290 P05.126

54. JM Bertoni, JP Arlette, HH Fernandez, K Frei, MF Gordon[5] MN Hassan, SH Isaacson**, MF Lew,** E Molho, WG Ondo, TJ Phillips, C Singer, JP Sutton, JE Wolf Jr, for the North American Parkinson's and Melanoma Survey Investigators Parkinson's Disease and Melanoma: An Epidemiologic Evaluation. AAN 2006

55. JM Bertoni, JP Arlette, HH Fernandez, K Frei, MF Gordon[5] MN Hassan, SH Isaacson, **MF Lew,** E Molho, WG Ondo, TJ Phillips, C Singer, JP Sutton, JE Wolf Jr. Epidimeologic association of Parkinson's disease and melanoma. Movement Disorders 2006 21 (Suppl 15) S610 P1019

56. **M.F. Lew** Tolcapone and the prevention of Depression in patients with early stage Parkinson's disease initiating levodopa. Movement Disorders 2006 21 **(**Suppl 15) S 657 P1187

57. Widner, Håkan, Wirdefeldt, Karin, Gatz, Margaret, Bakaysa, Stephanie L, Fiske, Amy, Flensburg, Måns, Petzinger, Giselle, M, **Lew, Mark F**,Welsh, Mickie, Pedersen, Nancy L, Parkinson's disease assessed in the Swedish Twin Registry Dopamine 50 years Goteborg, Sweden 6/07

58. **Lew, M F**, Kricorian,G, Sethi , K. Safety of Zydis selegiline orally disintegrating tablet (ODT) with concomitant antidepressant therapy in Parkinson's disease (PD), Movement Disorders 2007

59. **Lew, M.F**., Pappert, Eric J. Botulinum Toxin Type B:Effects on Pain Associated with Cervical Dystonia: A Meta-Analysis AAN 4/08 Chicago

60. D. Truong , **M. Lew,** O.Orlova,, and the International Cervical Dystonia Study Team. The Efficacy of Dysport® (Botulinum toxin type A) in the Treatment of Cervical Dystonia: A Phase III Multicenter, Randomized, Double Blind, Placebo-Controlled Study 12th International Congress of movement Disorders Chicago 6/08

61. Widner, Håkan, Wirdefeldt, Karin, Gatz, Margaret, Bakaysa, Stephanie L, Fiske, Amy, Flensburg, Måns, Petzinger, Giselle, M, **Lew, Mark F**,Welsh, Mickie, Pedersen, Nancy L, Parkinson's disease assessed in the Swedish Twin Registry 12th International Congress of movement Disorders Chicago 6/08

62. D.Truong, MD., **M.Lew,** Pr. O.Orlova, and the International CD Study Team. Efficacy of Dysport® (Botulinum toxin type A) for the Treatment of Cervical Dystonia: A Multicenter, Randomized, Double Blind, Placebo-Controlled Phase III Study. Toxins 2008 Baveno Italy 6/08

63. **Mark F. Lew,** Meg Corliss, Yuxing Zhang, and Edgar SalazarGrueso Botulinum toxin type B (BoNT-B) effects on pain in cervical dystonia: Results of placebo- and comparator controlled studies. American Academy of Pain Medicine Honolulu, Hawaii 1/09

64. Effects of Immediate Versus Delayed Switch From Levodopa/Carbidopa to Levodopa/Carbidopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off. **Mark F. Lew, MD**, Monique Somogyi, MD, Kevin McCague, MA, Mickie Welsh, DnSc AAN Seattle Washington, 4/09

65**.** Botulinum toxin type B (BoNT-B) effects on pain associated with cervical dystonia: Results of placebo- and comparator-controlled studies Meg Corliss, PhD, Yuxing Zhang, PhD and **Mark Lew, MD** Movement Disorders Society 13th meeting Paris, France , 6/09

66. Kenneth Shulman Katie Rolfe, **Mark Lew** Long-term follow up study of ropinirole prolonged release in patients with early or advanced Parkinson's disease: dose levels and patient compliance AAN Toronto April 2010

67**. Mark F. Lew**, Fernando Pagan, Robert Chinnapongse,,Sharon Reinhard, William Birmingham An Open-Label, Safety and Immunogenicity Study of Myobloc® (rimabotulinumtoxinB; BoNT-B) in Patients with Cervical Dystonia – (351) AAN Toronto April 2010

68) J. J. Ferreira**, M. F. Lew** Immunogenicity analysis from an extension of a randomised, double-blind trial comparing botulinum neurotoxin type B vs. type A in previously toxin-naive patients with cervical dystonia: study 402CD-EU First International Congress on Treatment of Dystonia, Hannover , Germany May 2010. J Neural Trans (2010) 117:1234

69) J. J. Ferreira, **M. F. Lew** An open-label safety and immunogenicity study of botulinum neurotoxin type B in patients with cervical dystonia: study 401CD-EU First International Congress on Treatment of Dystonia, Hannover , Germany May 2010. J Neural Trans (2010) 117:1234

70) **M.F. Lew** An open-label long-term safety and immunogenicity study of botulinum neurotoxin type B in patients with cervical dystonia: study 351 First International Congress on Treatment of Dystonia, Hannover , Germany May 2010. J Neural Trans (2010) 117:1237

71) **.M.F. Lew** A long-term open-label study of repeated dosing with botulinum neurotoxin type B in patients with cervical dystonia First International Congress on Treatment of Dystonia, Hannover , Germany May 2010. J Neural Trans (2010) 117:1237

Presentations

1. Suckling vs. free feeding: Preferences in developing albino rats. Eastern Psychological Association, 1979

2. Intracranial self-stimulation in three-day-old rat pups. International Society for Developmental Psychobiology, Cincinnati, Ohio, 1980

3. Gastric inhibitory polypeptide (GIP) suppresses real but not sham feeding in the rat. Eastern Psychological Association, Baltimore, MD. 1982

4. ^{18}Fluorodeoxyglucose positron emission tomography scanning in spasmodic dysphonia pre and post Botox™, 7th Annual Symposium on Etiology, Pathogenesis and prevention of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders, Boston, Massachusetts, October, 1993

5. A double-blind, placebo-controlled, single treatment, dose-finding, safety, tolerability and preliminary efficacy study of BotB ™ (Botulinum toxin type B) at various doses in patients with idiopathic cervical dystonia. 3rd International Dystonia Symposium, Miami, Florida, October, 1996

6. Safety and efficacy of NeuroBloc™ (botulinum toxin type-B) in type-A responsive and type-A resistant patients with cervical dystonia. International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Orlando, Florida, November, 1999

7. Quality of life in cervical dystonia: a comparison of the subjective and objective assessments. 13th Annual symposium on Etiology, Pathogenesis, and Treatment of Parkinson's disease, Seattle, Washington, October, 1999

8. Efficacy of botulinum toxin type B in decreasing pain associated with cervical dystonia. Worldwide Pain Conference 2000, San Francisco, July, 2000

9. Botulinum Toxin Type B (MYOBLOC™): Efficacy and safety of a new botulinum neurotoxin. International Symposium on Cosmetic Botulinum Toxin for the Expert, Vancouver, British Columbia, Canada, October, 2000

10. Analysis of the duration of efficacy of botulinum toxin type B (BoNT-B) in patients with cervical dystonia. 4th International Dystonia Symposium, Atlanta, Georgia, June, 2002

11. A controlled trial of rasagiline in Parkinson's disease patients with levodopa-related motor fluctuations (PRESTO study). Poster presentation, annual ANA Meeting, San Francisco, California, October 2003

12. Dopamine-related behavioral disorders in Parkinson's. Poster presentation (P808), 8th International Congress of Parkinson's Disease and Movement Disorders, Rome, Italy, June 2004

13. Long term efficacy and safety of Zydis® selegine in Parkinson's disease (PD). Poster presentation (P348), 8th International Congress of Parkinson's Disease and Movement Disorders, Rome, Italy, June 2004

14. Long-term efficacy of rasagiline in Parkinson's disease. (P250) 9th International Congress of Parkinson's Disease and Movement Disorders, New Orleans, Louisiana, March 2005

15. Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease. (P251). 9th International Congress of Parkinson's Disease and Movement Disorders, New Orleans, Louisiana, March 2005

16. Results from a 2-year centralized tolcapone liver enzyme monitoring program. (P404) 9th International Congress of Parkinson's Disease and Movement Disorders, New Orleans, Louisiana, March 2005

17. Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease. (P02.104) 57th Annual Meeting AAN, Miami, Fla 2005

18. Long-term efficacy of rasagiline in Parkinson's disease. (S47.005) 57th Annual Meeting AAN, Miami, Fla 2005

19. Long term efficacy of rasagiline in Parkinson's disease patients. Poster presentation (PT-006-10),16th International Congress on Parkinson's Disease and Related Disorders, Berlin, June 2005

20. Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease: Analysis of the TEMPO ITT cohort (PT-006-11), International Congress on Parkinson's Disease and Related Disorders, Berlin, June 2005

21. Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease: Analysis of the TEMPO ITT cohort Platform Presentation (SC116), 9th Congress of the European Federation of Neurological Societies, Athens, Greece, September 2005

22. Long-term efficacy of rasagiline in Parkinson's disease patients Platform Presentation (SC117) 9th Congress of the European Federation of Neurological Societies, Athens, Greece, September 2005

23. Long-term safety and Efficacy of a novel MAO-B inhibitor in the treatment of Parkinson's disease (P280) American Neurological Association 130th meeting, San Diego, Ca Sept 2005

24. Results from a 2 year centralized tolcapone liver enzyme monitoring system. (P1035) 18th World Congress of Neurology, Sydney, Australia November 2005

25. Long-Term treatment of Parkinson's disease with a novel MAO-B Inhibitor: Analysis of Safety and Efficacy. (P1036) 18th World Congress of Neurology, Sydney, Australia November 2005

26. A 4 year observational study of repeated dosing with botulinum toxin type B in patients with cervical dystonia. P05.126 58th Annual Meeting AAN, San Diego, Ca April 2006